Potential Impact of Benzodiazepine Use on the Rate of Hip Fractures in Five Large European Countries and the United States
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Benzodiazepine use increases the risk of falls and has been associated with an increased risk of hip fractures. Our aim was to estimate the possible population impact of the use of benzodiazepines on the rate of hip fracture in France, Germany, Italy, Spain, the United Kingdom, and the United States. We conducted a literature review to estimate the pooled relative risk (RR) for hip fractures and use of benzodiazepines. Prevalence rates of benzodiazepine use in 2009 were calculated for each country using the IMS MIDAS database and three public databases in Denmark, the Netherlands, and Norway. Both the RR and prevalence rates were used for calculation of population attributable risks (PARs) of hip fractures associated with benzodiazepine use. The literature review showed an increased risk of hip fractures in benzodiazepine users (RR = 1.4, 95 % CI 1.2-1.6). Rate of benzodiazepine use showed considerable differences between countries, ranging from 4.7 % to 22.3 % of population ever in a 1-year period. These are reflected in results for the PARs; estimated attributions of benzodiazepines to the rate of hip fractures were 1.8 %, 95 % CI 1.1-2.6 (Germany); 2.0 %, 95 % CI 1.2-2.8 (United Kingdom); 5.2 %, 95 % CI 3.2-7.3 (Italy); 7.4 %, 95 % CI 4.5-10.0 (France); 8.0 %, 95 % CI 4.9-11.0 (United States); and 8.2 %, 95 % CI 5.1-12.0 (Spain). PAR estimates suggest that the potential attribution of benzodiazepine use on the population rate of hip fractures in the five specified European countries and the United States varies between 1.8 % and 8.2 %. During the next phase of the IMI-PROTECT study, a comparison with individual patient data will show whether this approach is valid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595 · cited 1×
“Some studies found an increased risk for both benzodiazepine types, with higher risks for LABS compared to SABs [34, 35, 40].”
BackgroundWang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.892 · Cited by 312
Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132
Cited by
Low back pain in older adults: risk factors, management options and future directions
Wong, A. Y., Karppinen, J., & Samartzis, D. (2017) · Scoliosis and Spinal Disorders · doi:10.1186/s13013-017-0121-3 · Cited by 456
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356
“sumption in the US and five European countries [47].”
BackgroundBenzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225
“The current literature base illustrates that there is an increased risk of hip fracture following BNZ use [27, 28] and zolpidem use [29] respectively.”
BackgroundPsychotropic medicine consumption in 65 countries and regions, 2008-19: A longitudinal study
Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., Chui, C. S. L., Hayes, J. F., Man, K. K. C., Lau, W. C. Y., Yan, V. K. C., Beykloo, M. Y., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00292-3 · Cited by 203
Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002−2014
Hwang, C. S., Kang, E. M., Kornegay, C. J., Staffa, J. A., Jones, C. M., & McAninch, J. K. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.02.014 · Cited by 190
Kroll, D. S., Nieva, H. R., Barsky, A. J., & Linder, J. A. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3740-0 · Cited by 94
“Hospitalizations Patients with hospitalizations (%) 1202 (12) 4631 (8) <0.”
BackgroundDriessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79
“…were considered potential confounders; oral glucocorticoids [19], cholesterol lowering drugs, antidepressants [20], anxiolytics or hypnotics [21], antipsychotics, anti-Parkinson drugs [22], antihyperten-sives (beta-blockers, thiazide diuretics, renin-angiotensin-aldosterone-system (RAAS)…”
Vicens, C., Leiva, A., Bejarano, F., Sempere-Verdú, E., Rodríguez-Rincón, R. M., Fiol, F., Mengual, M., Ajenjo-Navarro, A., Do Pazo, F., Mateu, C., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1003983 · Cited by 15
Metadata
- Authors
- Khong, T. P., de Vries, F., Goldenberg, J. S. B., Klungel, O. H., Robinson, N. J., Ibáñez, L., & Petri, H.
- Venue
- Calcified Tissue International
- Published
- 2012-05-08
- Volume
- 91
- Issue
- 1
- Pages
- 24-31
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2157877777
- Cited by
- 87
- References
- 3
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.